Pre-made Afasevikumab benchmark antibody ( Whole mAb, anti-IL17A/IL17 therapeutic antibody, Anti-CTLA-8/CTLA8A/ILA17 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-012

Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-012-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
INN Name Afasevikumab
TargetIL17
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI Structure6ppg:HL:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesNovImmune;Genentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Inflammation
Development Techna